AiRuiKa (camrelizumab)

However, the sample size is relatively small and needs to be increased for further research. https://clinicaltrials.gov/study/NCT03986515, identifier NCT03986515.

Neoadjuvant RC48 plus camrelizumab and S-1 showed encouraging pathological responses in HER2-overexpressing gastric cancer. The regimen achieved a pCR rate of 25% and an MPR rate of 45.8%. The combination therapy demonstrated a manageable safety profile. Exploratory ctDNA methylation analysis suggested potential for dynamic response monitoring.

Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs. The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.

P3, N=188, Recruiting, Sun Yat-sen University | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2024 --> Jun 2027

P2, N=28, Not yet recruiting, Sun Yat-sen University

In IMbrave050, adjuvant atezolizumab plus bevacizumab initially improved recurrence-free survival (RFS), yet longer follow-up suggests attenuation of effect, influencing guideline recommendations. Perioperative combinations are emerging, including camrelizumab plus rivoceranib with improved event-free survival, and locoregional-immunotherapy strategies such as transarterial chemoembolization combined with immunotherapy-antiangiogenic regimens. Biomarker-driven selection, circulating tumor DNA for minimal residual disease, resistance-associated alterations (e.g., CTNNB1), and etiology-linked immune phenotypes, will be central to optimizing patient selection and treatment sequencing.

P2, N=39, Completed, Chongqing University Cancer Hospital | Recruiting --> Completed | N=30 --> 39 | Trial completion date: Jan 2027 --> Feb 2026 | Trial primary completion date: Jan 2025 --> Feb 2026

Camrelizumab plus nab-paclitaxel demonstrated modest antitumor activity along with manageable toxicity in patients with previously treated aUC. Trial registration: This trial was registered at www.chictr.org.cn (Identifier: CTR2000033820, registration date: 2020 June 13).

Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.

P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028

P=N/A, N=84, Hefei Cancer Hospital, Chinese Academy of Sciences; Hefei Cancer Hospital, Chinese Academy of Sciences

P4, N=50, Completed, Suzhou Municipal Hospital; Suzhou Municipal Hospital